Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150816 | 1.00 | LMNA (0.42) | LMNAAPPGBA1GAA | |
| SCHEMBL5150809 | 1.00 | LMNA (0.42) | LMNAAPPGBA1GAA | |
| SCHEMBL27913293 | 0.78 | LMNA (0.46) | LMNAAPPGBA1GAA | |
| SCHEMBL27895828 | 0.78 | LMNA (0.46) | LMNAAPPGBA1GAA | |
| SCHEMBL15617775 | 0.77 | FUCA1 (0.33) | — | |
| SCHEMBL27913288 | 0.77 | — | — | |
| SCHEMBL439753 | 0.75 | LMNA (0.42) | LMNAAPPGBA1GAA | |
| SCHEMBL27895821 | 0.72 | — | — | |
| SCHEMBL27913349 | 0.72 | — | — | |
| SCHEMBL2461938 | 0.69 | LMNA (0.36) | LMNAAPPGBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108018265-A | A kind of inositol oxidation enzyme mutant and its encoding gene and application | 山东大学 | 2018-05-11 | — | — | CN | claimed |
| US-7825270-B2 | Inositolphospholipids and analogues: phosphatidylinositol products and processes | NUTRIMED BIOTECH (US) | 2010-11-02 | — | — | US | claimed |
| WO-2007073559-A2 | INOSITOLPHOSPHOLIPIDS AND ANALOGUES: PHOSPHALIDYLINOSITOL PRODUCTS AND PROCESSES | NUTRIMED BIOTECH (US) | 2007-06-28 | — | — | WO | claimed |
| US-20070142653-A1 | Inositolphospholipids and Analogues: Phosphatidylinositol Products and Processes | NUTRIMED BIOTECH (US) | 2007-06-21 | — | — | US | claimed |
| EP-0730460-B1 | THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | PERSTORP AB (SE) | 2002-06-12 | — | — | EP | claimed |
| US-5866557-A | REDUCE TISSUE DAMAGE | PERSTORP AB (SE) | 1999-02-02 | — | — | US | claimed |
| US-5846957-A | Use of an ester of inositoltrisphosphate for the preparing of medicaments | PERSTORP AB (SE) | 1998-12-08 | — | — | US | claimed |
| US-5214180-A | Plant extracts, protecting hydroxy groups, solvent extraction, chromatography | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-05-25 | — | — | US | claimed |
| EP-0516914-A2 | Highly pure phosphatidylinositol of natural source useful for the treatment of central nervous system disorders and process for its preparation | MEDIOLANUM FARMACEUTICI s.r.l. (IT) | 1992-12-09 | — | — | EP | claimed |
| JP-5097875-A | — | — | None | — | — | JP | disclosed |
| WO-2024047037-A1 | COMPOSITIONS FOR PARENTERAL SUSTAINED RELEASE DELIVERY OF HYDROPHILIC DRUGS | ETH Zürich (CH) | 2024-03-07 | — | — | WO | disclosed |
| EP-3503880-B1 | COMPOUNDS FOR TREATMENT OF INTRACTABLE EPILEPSY AND DOORS SYNDROME | VIB VZW (BE) | 2023-12-27 | — | — | EP | disclosed |
| CN-112135633-A | Phytate for use as a biomolecule delivery or adsorption system | 禾大国际股份公开有限公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200093843-A1 | COMPOUNDS FOR TREATMENT OF INTRACTABLE EPILEPSY AND DOORS SYNDROME | VIB VZW (BE) | 2020-03-26 | — | — | US | disclosed |
| US-5214180-A | Plant extracts, protecting hydroxy groups, solvent extraction, chromatography | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-05-25 | — | — | US | disclosed |
| JP-H0597875-A | HIGH PURITY PHOSPHATIDYLINOSITOL FROM NATURAL SOURCE USEFUL FOR TREATING CENTRAL NERVOUS SYSTEM DISORDER AND ITS PREPARATION | MEDIOLANUM FARMACEUT SRL | 1993-04-20 | — | — | JP | disclosed |
| EP-0516914-A2 | Highly pure phosphatidylinositol of natural source useful for the treatment of central nervous system disorders and process for its preparation | MEDIOLANUM FARMACEUTICI s.r.l. (IT) | 1992-12-09 | — | — | EP | disclosed |
| EP-0516914-A2 | Highly pure phosphatidylinositol of natural source useful for the treatment of central nervous system disorders and process for its preparation | MEDIOLANUM FARMACEUTICI s.r.l. (IT) | 1992-12-09 | — | — | EP | disclosed |
| WO-1991016920-A1 | LIPID PRODRUGS OF SALICYLATE AND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | VICAL, INC. (US) | 1991-11-14 | — | — | WO | disclosed |
| US-4924023-A | MEDICINE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142653-A1 | Inositolphospholipids and Analogues: Phosphatidylinositol Products and Processes | PLCB3, INPPL1, PLCB1 | LMNA 986/4885APP 810/4885GBA1 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.